Regeneron Tops Q1 Estimates on Dupixent Momentum [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Adjusted earnings per share came in at $9.47, ahead of the analyst consensus of $8.97 by $0.50. Revenue reached $3.6 billion, up 19% year over year from $3.0 billion and above the $3.48 billion estimate. Shares rose 1.4% following the announcement. Global net sales of Dupixent, recorded by Sanofi, climbed 33% to $4.9 billion, driving a 36% increase in collaboration revenue to $1.6 billion. In contrast, combined U.S. net sales of EYLEA HD and EYLEA declined 10% to $941 million. EYLEA HD sales rose 52% to $468 million, while legacy EYLEA revenue dropped 36% to $473 million due to competitive pressures and ongoing patient transitions to the newer formulation. “In the first quarter of this year, we were able to achieve strong double-digit growth on both the top and bottom line while continuing to invest significant resources in our portfolio of nearly 50 product candidates in clinical development,” said Leonard S. Schleifer. The company's GAAP gross margin on net product sales de
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Regeneron Pharmaceuticals Q1 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Regeneron's C5 Milestones And Autoimmune Bets Shape Future Valuation [Yahoo! Finance]Yahoo! Finance
- Regeneron (NASDAQ:REGN) Reports Strong Q1 CY2026 [Yahoo! Finance]Yahoo! Finance
- Regeneron Reports First Quarter 2026 Financial and Operating Results [Yahoo! Finance]Yahoo! Finance
- Regeneron Reports First Quarter 2026 Financial and Operating ResultsGlobeNewswire
REGN
Earnings
- 4/29/26 - Beat
REGN
Sec Filings
- 4/29/26 - Form 10-Q
- 4/29/26 - Form 8-K
- 4/24/26 - Form ARS
- REGN's page on the SEC website